Cargando…
Oral surveillance and JAK inhibitor safety: the theory of relativity
The published results of the post-marketing ORAL Surveillance study, which compared the Janus kinase (JAK) inhibitor tofacitinib with anti-TNF therapy in older patients with rheumatoid arthritis who have cardiovascular risk factors, have led to changes in the recommendations for the use of JAK inhib...
Autores principales: | Winthrop, Kevin L., Cohen, Stanley B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939241/ https://www.ncbi.nlm.nih.gov/pubmed/35318462 http://dx.doi.org/10.1038/s41584-022-00767-7 |
Ejemplares similares
-
Will JAK1/2 inhibitors change the standard of care for myelofibrosis?
por: Jung, Chul Won
Publicado: (2012) -
Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
por: Passamonti, Francesco, et al.
Publicado: (2011) -
Progress of Active Surveillance for Vaccine Safety in China
por: Liu, Zhike, et al.
Publicado: (2021) -
The Importance of Active Surveillance in the Assessment of Vaccine Safety
por: Black, Steven
Publicado: (2019) -
TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
por: Wu, Dandan, et al.
Publicado: (2020)